- Home
- LIN vs NVO Comparison
LIN vs NVO Comparison
Compare LIN & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LIN | NVO |
|---|---|---|
| Founded | 1879 | 1923 |
| Country | United Kingdom | Denmark |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.2B | 212.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LIN | NVO |
|---|---|---|
| Price | $444.15 | $58.96 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 10 |
| Target Price | ★ $503.09 | $54.25 |
| AVG Volume (30 Days) | 3.0M | ★ 17.4M |
| Earning Date | 02-05-2026 | 02-04-2026 |
| Dividend Yield | 1.36% | ★ 2.15% |
| EPS Growth | ★ 13.37 | 10.06 |
| EPS | ★ 14.94 | 3.67 |
| Revenue | $33,504,000,000.00 | ★ $49,580,393,058.00 |
| Revenue This Year | $3.66 | $7.25 |
| Revenue Next Year | $4.98 | $0.24 |
| P/E Ratio | $29.43 | ★ $15.64 |
| Revenue Growth | 1.45 | ★ 16.64 |
| 52 Week Low | $387.78 | $43.08 |
| 52 Week High | $486.38 | $93.80 |
Technical Indicators
Market Signals| Indicator | LIN | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 70.96 | 75.98 |
| Support Level | $432.41 | $50.55 |
| Resistance Level | $429.46 | $58.15 |
| Average True Range (ATR) | 5.68 | 1.28 |
| MACD | 2.30 | 0.87 |
| Stochastic Oscillator | 96.79 | 87.13 |
Price Performance
Historical ComparisonAbout LIN Linde plc
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $33 billion in revenue in 2024.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.